Enhanced muscle regeneration using stem cells

Kyoto University
The Hidetoshi Sakurai laboratory reports two new markers that should advance iPS cell therapies for muscle degeneration.
Muscular dystrophy describes a group of muscle degenerative congenital diseases. The severity and rates differ between disease and patient, but in all cases the degeneration progresses, sometimes leaving patients in wheelchairs and unable to breathe without artificial respiration. With no present cure, scientists are experimenting with the transplantation of muscle progenitor cells, but the amounts needed can only be made from stem cells such as iPS cells. A new study by CiRA Associate Professor Hidetoshi Sakurai and colleagues report two cell surface receptors, CDH13 and FGFR4, that are expected to advance iPS cell therapies for these diseases.

Related Keywords

Japan ,Kyoto ,Mingming Zhao ,Akitsu Hotta ,Naoshi Sugimoto ,Antonio Lucena Cacace ,Tatsuya Jonouchi ,Hidetoshi Sakurai ,Takuma Mizusawa ,Mitsuru Sasaki Honda ,Minas Nalbandian ,Masahiko Yasuda ,Yoshinori Yoshida ,Department Of Clinical Application ,Kyoto University ,Central Institute For Experimental Animals ,Department Of Cell Growth ,Professor Hidetoshi Sakurai ,Stem Cell ,Myogenic Cell Purification Toward ,Clinical Application ,Cell Growth ,Experimental Animals ,ஜப்பான் ,கியோட்டோ ,அன்டோனியோ ழூசெனா காஸாஸ் ,துறை ஆஃப் மருத்துவ விண்ணப்பம் ,கியோட்டோ பல்கலைக்கழகம் ,மைய நிறுவனம் க்கு சோதனை விலங்குகள் ,துறை ஆஃப் செல் வளர்ச்சி ,தண்டு செல் ,மருத்துவ விண்ணப்பம் ,செல் வளர்ச்சி ,சோதனை விலங்குகள் ,